In head and neck squamous cell carcinoma (HNSCC) cells, one study demonstrated that the activation of EGFR results in the phosphorylation of one of the core Hippo pathway components, MOB1, which hinders the function of LATS1/2, consequently leading to the aberrant activation of YAP/TAZ independently of EGFR’s typical signaling targets, including PI3K (Ando et al., 2021). Here, EGFR is linked to head and neck squamous cell carcinoma.